Paper
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress

https://doi.org/10.1016/0959-8049(94)90182-1Get rights and content

Abstract

The Memorial Syptom Assessment Scale (MSAS) is a new patient-rated instrument that was developed to provide multidimensional information about a diverse group of common symptoms. This study evaluated the reliability and validity of the MSAS in the cancer population. Randomly selected inpatients and outpatients (n = 246) with prostate, colon, breast or ovarian cancer were assessed using the MSAS and a battery of measures that independently evaluate phenomena related to quality of life. Symptom prevalence in the 218 evaluable patients ranged from 73.9% for lack of energy to 10.6% for difficulty swallowing. Based on a content analysis, three symptoms were deleted and two were added; the revised scale evaluates 32 physical and psychological symptoms. A factor analysis of variance yielded two factors that distinguished three major symptom groups and several subgroups. The major groups comprised psychological symptoms (PSYCH), high prevalence physical symptoms (PHYS H), and low prevalence physical symptoms (PHYS L). Internal consistency was high in the PHYS H and PSYCH groups (Cronback α coefficients of 0.88 and 0.83, respectively), and moderate in the PHYS L group (α = 0.58). Although the severity, frequency and distress dimensions were highly intercorrelated, canonical correlations and other analyses demonstrated that multidimensional assessment (frequency and distress) augments information about the impact of symptoms. High correlations with clinical status and quality of life measures support the validity of the MSAS and indicate the utility of several subscale scores, including PSYCH, PHYS, and a brief Global Distress Index. The MSAS is a reliable and valid instrument for the assessment of symptom prevalence, characteristics and distress. It provides a method for comprehensive symptom assessment that may be useful when information about symptoms is desirable, such as clinical trials that incorporate quality of life measures or studies of symptom epidemiology.

References (40)

  • SM Hunt et al.

    The Nottingham health profile: subjective health status and medical consultations

    Soc Sci Med

    (1981)
  • C Peruselli et al.

    Qualify of life assessment in a home care program for advanced cancer patients: a study using the Symptom Distress Scale

    J Pain Symptom Manage

    (1993)
  • EB Curtis et al.

    Common symptoms in patients with advanced cancer

    J Palliat Care

    (1991)
  • KP Dunphy et al.

    A comparison of hospice and homecare patients: patterns of referral, patient characteristics and predictors of place of death

    Palliat Med

    (1990)
  • GM Dunlop

    A study of the relative frequency and importance of gastrointestinal symptoms and weakness in patients with far-advanced cancer: student paper

    Palliat Med

    (1989)
  • DB Reuben et al.

    Clinical symptoms and length of survival in patients with terminal cancer

    Arch Intern Med

    (1988)
  • LR Derogatis et al.

    The prevalence of psychiatric disorders among cancer patients

    J Am Med Assoc

    (1983)
  • TJ Craig et al.

    Psychiatric symptomatology among hospitalized cancer patients

    Am J Psych

    (1974)
  • PM Levine et al.

    Mental disorders in cancer patients: a study of 100 psychiatric referrals

    Cancer

    (1978)
  • MJ Massie et al.

    Overview of normal reactions and prevalence of psychiatric disorders

  • DF Cella et al.

    Measuring quality of life today: methodological aspects

    Oncology

    (1990)
  • CM Moinpour et al.

    Quality of life end points in cancer clinical trials: review and recommendations

    J Natl Cancer Inst

    (1989)
  • NK Aaronson et al.

    Multidimensional approach to the measurement of quality of life in lung cancer clinical trials

  • K Donovan et al.

    Measuring quality of life in cancer patients

    J Clin Oncol

    (1989)
  • SG Nayfield et al.

    Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials

    Qual Life Res

    (1992)
  • KC Calman

    Definitions and dimensions of quality of life

  • NK Aaronson et al.

    The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology

    J Natl Cancer Inst

    (1993)
  • H Schipper et al.

    Measuring the quality of life of cancer patients: the functional living index-cancer. Development and validation

    J Clin Oncol

    (1984)
  • PA Ganz et al.

    The CARES: a generic measure of health-related quality of life for patients with cancer

    Qual Life Res

    (1992)
  • DF Cella et al.

    The functional assessment of cancer therapy scale: development and validation of the general measure

    J Clin Oncol

    (1993)
  • Cited by (0)

    View full text